Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) has announced today that it has signed a long-term service agreement with oil tanker shipping firm Maran Tankers Management Inc. Under the five-year agreement, Nikkiso CE&IG will deliver comprehensive global aftermarket support for Maran Tankers’ high pressure pumps, including scheduled cold end valve repairs at defined intervals. To guarantee minimal turnaround time, Nikkiso CE&IG will maintain critical inventory a...

Boomi™, the data activation company, today announced the winners of its FY26 APJ Partner Awards. The program celebrates Boomi partners that are driving innovation and delivering measurable business outcomes for customers across the region. The awards highlight organizations that are leveraging the full breadth of the Boomi Enterprise Platform to activate data, simplify complexity, and accelerate agentic transformation — enabling customers to innovate faster, address evolving business challeng...

MMS Holdings, a global, data-focused clinical research organization (CRO), today named UK-based Ben Dudley as President, extending his existing role as Chief Commercial Officer. The expanded position further supports MMS’ vision and growth as a science-led CRO, helping sponsors worldwide navigate complexity, reduce risk, and advance clinical programs through its integrated biometrics and regulatory capabilities. Dudley’s appointment reinforces MMS’ increasing international presence and builds o...

Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee...

Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide. Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and supported by established qu...

Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now return...

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and acces...

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and prop...

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an In...